Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Said To Deny Visas To U.S. Trade Panel To Probe IP Rights Issues

This article was originally published in PharmAsia News

Executive Summary

India reportedly has decided to stiff-arm U.S. International Trade Commission officials who have sought visas to visit India and investigate its trade and industrial practices related to intellectual property.

You may also be interested in...



Teva, Sandoz And Accord Take COVID-19 Action

While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.

Coronavirus Pandemic Accelerating Shift To Digitally-Enabled Innovation

Virtual trials could be the answer to limitations placed on innovation by the coronavirus pandemic and help companies formulate new health claims relevant to a new generation of consumers, argued IQVIA Consumer Health during a recent webinar. 

Coronavirus Update: Lilly Begins Clinical Trial Of Antibody Therapy

Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.

Topics

UsernamePublicRestriction

Register

AP007430

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel